A defining feature of the COVID-19 pandemic has been the wide spectrum of clinical presentations, ranging from asymptomatic viremia to life-threatening illness.1 Factors such as advancing age and co-morbid status have […]
The Emerging Evidence for a Genetic Susceptibility to Severe Covid-19. St Emlyn’s Read More
A core skill in emergency medicine is in the identification and classification of risk categories for the patients we see. For many conditions we have derived, validated and refined scoring
Risk stratification in the ED for COVID19 patients: The PRIEST study. St Emlyn’s Read More
I am sure many of you saw the breaking news on the BBC the other week, about a new wonderdrug to strengthen our defences against the tidal wave that is
Tocilizumaybe? Immune modulation in COVID-19 Read More
This month the BMJ has published a trial on the use of convalescent plasma in the treatment of admitted patients with COVID-19 (the PLACID trial). Convalescent plasma therapy basically takes
JC: Convalescent plasma in COVID 19 patients. Read More
We previously covered the RECOVERY trial press release on the use of HCQ for hospitalised patients with COVID19. This is a UK based platform trial (more on this later) looking
JC: Hydroxychloroquine in the the treatment of hospitalised COVID19 patients. Read More
Tranexamic Acid (TXA) is a mainstay of trauma management. CRASH 2 (2) demonstrated its effectiveness in bleeding patients and CRASH 3 (1,5) (in my opinion) showed that we should also
JC: Can we give tranexamic acid (TXA) via the IM route? St Emlyn’s Read More
Our post on the CRASH-3 trial, an RCT examining the use of TXA in head injury, was arguably our most controversial of 2019 (1). Our view was that the evidence
JC: TXA in severe head injury. St Emlyn’s Read More
This week JAMA published three important trials on the use of steroids in patients with severe COVID-19, with an additional cherry on top; a subsequent inclusive meta-analysis (totalling 7 RCTs
The ‘Roid’ to Recovery? REMAP-CAP @ St Emlyn’s Read More
